Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being…
Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked…
Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community
SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
September 04, 2025 20:00 ET Â | Source: HUTCHMED (China) Limited HONG KONG…
Zai Lab Announces Approval of TIVDAK for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today…
850-mile cycle for Manchester man in memory of his twin and his dad
Friday 29 August, 2025 A man from Manchester, who lost both his…
Scientists Discuss the Recent CancerVax Breakthrough
The Company's scientific team describes how they successfully disguised cancer cells and…
From Vision to Victory: Celebrating India’s Most Impactful Achievers Unveiled by Kiteskraft Productions LLP
CHANDIGARH, India, Aug. 18, 2025 /PRNewswire/ -- India's growth story is being…
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
  - Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the…